Abstract: The invention relates in particular to an in vitro or ex vivo method for predicting the response of a patient to treatment with at least one HER2-blocking agent, said method including the steps of: i) identifying the nucleotide at the rs3746083 polymorphic site, for at least one allele, in particular the two alleles of the gene coding the tristetraprolin protein, in a biological sample from said patient; and/or ii) determining the concentration of the tristetraprolin protein in a biological sample from said patient, wherein said patient is suffering from HER2-positive cancer.

Abstract: The invention provides an isolated antibody or a fragment thereof, which is directed to the human chemokines CXCL1, CXCL7 and CXCL8, said antibody or fragment being capable of binding to the human chemokine CXCL1 with an equilibrium dissociation constant (KD) of at most 16 nM, to the human chemokine CXCL7 with an equilibrium dissociation constant (KD) of at most 5 nM and to the human chemokine CXCL8 with an equilibrium dissociation constant (KD) of at most 45 nM, as determined by surface plasmon resonance. The invention also provides some applications of said isolated antibody.

Abstract: A method for supervised classification of cells contained in first and second different microscopy image formats preprocessing carried out on the basis of the first and second different image formats aiming to characterize their cell-related visual content and to transform the content into digital data; and executing a UNN algorithm-related code with the aim of processing the digital data.

Abstract: The invention relates in particular to an in vitro or ex vivo method for predicting the response of a patient to treatment with at least one HER2-blocking agent, said method including the steps of: i) identifying the nucleotide at the rs3746083 polymorphic site, for at least one allele, in particular the two alleles of the gene coding the tristetraprolin protein, in a biological sample from said patient; and/or ii) determining the concentration of the tristetraprolin protein in a biological sample from said patient, wherein said patient is suffering from HER2-positive cancer.

Abstract: According to one aspect, the invention relates to a device (20) for synchronizing optical pumping entanglement sources (141, 142) in a quantum communication network, including a pulsed light source (21) enabling the emission of telecom-wavelength light pulses (I1,I2), which are distributed in parallel with all of the entanglement sources in order to provide an optical clock common to said entanglement sources and including, for each entanglement source, a device (243, 253) for converting the frequency of the distributed light pulse, thereby enabling a light pulse to be generated at a wavelength adapted to the optical pumping of the entanglement source in order to generate pairs of entangled photons.

Abstract: The present disclosure provides in vitro methods of diagnosing a Plasmodium infection in a subject. The methods include measuring the serum concentration of at least one secreted phospholipase A2 selected from the group consisting of GIIF, GV and GX sPLA2s, in a blood sample from the subject. The disclosure also relates to a kit for carrying out the disclosed methods and pharmaceutical compositions comprising a recombinant mammalian GIIF, GV or GX sPLA2, or a combination thereof.

Abstract: A peptide with the following sequence YCQKFLWTCDSERPCCEGLVCRLWCKIN (SEQ ID NO 1) or a derivative thereof, and nucleic acids coding for the peptide having the sequence (SEQ ID NO 1). Also the use of this peptide as an antagonist and/or reverse agonist of T-type calcium channels. A use of the peptide for preparing a drug, in particular an analgesic one.

Abstract: The disclosure relates to a method for treating digital data, including a quantification step of calculating, in a space of dimension d, at least one vector index I1 for at least some of the vectors 1, the vectors 1 forming input data descriptors. The method is characterized in that the vector index I1 corresponds to the number of vectors preceding the vector 1 in the reverse lexicographic order, without involving a step of determining all of the vectors.

Abstract: The present invention relates to the process for preparing a boronic acid or ester chemically, in which an aromatic compound is reacted with a boronating agent, in the presence of magnesium metal (Mg0). The invention also relates to the boronic acids or esters that can be obtained by means of this process and to the use thereof for example as a synthesis intermediate, in the Suzuki reaction, in the pharmaceutical or alternatively electronics field.

Abstract: The invention concerns adult multipotent human stem cells, characterized in that they have: i) significant telomerase activity, ii) an HLA Class I negative phenotype, iii) a normal karyotype, iv) a capacity to become quiescent, v) a capacity for self-renewal preserved for at least 130 population doublings.

Abstract: The present invention relates to an in vitro method of diagnosis of a Plasmodium infection in a subject, by measuring the serum concentration of at least one secreted phospholipase A2 selected from the group consisting of GIIF, GV and GX sPLA2s, in said subject, from a blood sample. It also relates to a kit for carrying out said method and pharmaceutical compositions comprising a recombinant mammal GIIF, GV or GX sPLA2 or a combination thereof.

Abstract: The invention relates to a peptide derived from neurotensin receptor 3 (NTSR3), and to the use thereof in the treatment of psychiatric diseases. The present invention particularly relates to the use of this peptide for producing a drug, such as an antidepressant. The peptide of the invention is characterized in that the sequence thereof is the attached SEQ ID No. 2. The present invention can be used in the fields of the pharmaceutical industry and particularly in the field of drug development for treating psychiatric diseases. The present invention can also be used in the development of a novel antidepressant. It can also be used for example, in the treatment of pain and inflammations.

Abstract: A peptide with the following sequence YCQKFLWTCDSERPCCEGLVCRLWCKIN (SEQ ID NO 1) or a derivative thereof, and nucleic acids coding for the peptide having the sequence (SEQ ID NO 1). Also the use of this peptide as an antagonist and/or reverse agonist of T-type calcium channels. A use of the peptide for preparing a drug, in particular an analgesic one.

Abstract: A composition including diazoxide (7-chloro-3-methyl-2H-1,2,4-benzothiadiazine-1,1-dioxide) for the treatment and/or prevention of retinal ischemia and of diseases associated with retinal ischemia. The composition can also contain riluzole, a derivative active in neuroprotection of the latter, or a pharmaceutically acceptable salt of the latter.

Abstract: The present invention relates to the process for preparing a boronic acid or ester chemically, in which an aromatic compound is reacted with a boronating agent, in the presence of magnesium metal (Mg0). The invention also relates to the boronic acids or esters that can be obtained by means of this process and to the use thereof for example as a synthesis intermediate, in the Suzuki reaction, in the pharmaceutical or alternatively electronics field.

Abstract: The invention relates to a peptide derived from neurotensin receptor 3 (NTSR3), and to the use thereof in the treatment of psychiatric diseases. The present invention particularly relates to the use of this peptide for producing a drug, such as an antidepressant. The peptide of the invention is characterized in that the sequence thereof is the attached SEQ ID No. 2. The present invention can be used in the fields of the pharmaceutical industry and particularly in the field of drug development for treating psychiatric diseases. The present invention can also be used in the development of a novel antidepressant. It can also be used for example, in the treatment of pain and inflammations.

Abstract: The disclosure relates to a method for estimating the number of leader vectors with norm Ip equal to r6p,d, of dimension d, having co-ordinates which are lower than, or equal to k. The method is characterised in that r p delta, d is determined by the sum of the results of a function T(Xi) for i varying between 1 and d, the function T(Xi) providing, for at least some of the leader vectors, the result of the division of the co-ordinate Xi raised to the power p by a delta precision factor, the result of the division being rounded to the nearest whole number. The method does not comprise a step of determining leader vectors.

Abstract: The subject matter of the invention is a functional population of human brown adipocytes, in which the expression of UCP1, CIDEA, CPT1B and Bcl2 is higher, the expression of Bax is lower and the expression of PPAR-alpha, PGC-1alpha, PGC-1beta and PRDM16 is similar compared with the corresponding expressions of a population of human white adipocytes. The invention also relates to a method for differentiation of hMADS cells into the functional population of human brown adipocytes, to a method for conversion of a population of human white adipocytes into the functional population of human brown adipocytes, and also to a method of screening for molecules capable of modulating the bodyweight in an individual.

Abstract: The invention relates to a mobile communicating object (A) belonging to a communications network and comprising processing means (PM). According to the invention, when a communication has been established with another communicating object (S) belonging to the network, the aforementioned processing means generate a repeater (Fi) at each site (Hi) through which they pass. Moreover, when the repeater is generated, the processing means associate a timing counter (CTF) therewith and configure said repeater such that: (i) it can store an identifier that is representative of the location of the next repeater (F(i+1)) or site (H(i+1)) in the chain of repeaters to which it belongs; and (ii) at the end of a selected duration of time, it transmits the location identifier of the next repeater (F(i+1)) or site (S(i+1)) to at least one location server (SL) in the network, so that it stores said identifier together with the primary identifier of the mobile object (A).

Abstract: The method for manufacturing a composite based on complexes of controlled stability over time using a fibrous inorganic matrix having tunnels and one or more organic compounds incorporated into said tunnels includes the following steps: the fibrous inorganic matrix having tunnels and the organic compound or compounds are provided; the fibrous inorganic matrix having tunnels is mixed with the organic compound or compounds so that said organic compound or compounds are incorporated into the tunnels of the fibrous inorganic matrix; the retention of the organic compound or compounds in said tunnels and their release therefrom by heating said mixture obtained, at a chosen temperature for a defined time, are controlled. The invention applies in particular in a preparation intended for cosmetic, pharmacological, nutri-therapeutic and agri-foodstuff, phytosanitary, petroleum or electronic usage or else in paints.